

Figure 1. Chemical structures of tested BFRs (*: [^{14}C]-radiolabel)



Figure 2. Cumulative dose recovered in the receptor fluid after a single application of A: [^{14}C]-TBBPA, B: [^{14}C]-EH-TBB, C: [^{14}C]-BEH-TEBP, or D: [^{14}C]-DBDPE to rat (●) or human (■) skin in vitro.



Figure 3. Characterization of [^{14}C]-radioactivity in EH-TBB samples. A: *In vitro* media contained only TBBA. B: *In vivo* skin extracts contained both EH-TBB and TBBA. Urine and feces contained only TBBA.

Table 1. Measured and calculated BFR bioavailable fractions (%).

		Rat (*in vitro*)	Rat (*in vivo*)	Human (*in vitro*)	Estimated Human bioavailability (*in vivo*)
TBBPA	Absorbed (%)	9 ± 2	14 ± 3	3 ± 2	*6 ± 3*
	Penetrated (%)	4 ± 1	8 ± 2	0.2 ± 0.02	
EH-TBB	Absorbed (%)	36 ± 6	10 ± 3	12 ± 9	*7 ± 3*
	Penetrated (%)	2 ± 0.5	11 ± 1	0.2 ± 0.1	
BEH-TEBP	Absorbed (%)	29 ± 2	8 ± 3	2 ± 0.2	*1 ± 0.2*
	Penetrated (%)	0.01 ± 0.002	1 ± 0.3	0.005 ± 0.001	
DBDPE	Absorbed (%)	17 ± 2	17 ± 9	12 ± 4	*18 ± 10*
	Penetrated (%)	3 ± 0.6	5 ± 2	4 ± 1	